Expertise in
14
conditions

Dr. Tian Y. Zhang

Oncology
University Of Texas Southwestern Medical Center At Dallas
2201 Inwood Rd, 
Dallas, TX 
Offers Telehealth
Expertise in
14
conditions
University Of Texas Southwestern Medical Center At Dallas
2201 Inwood Rd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tian Zhang is an Oncologist in Dallas, Texas. Dr. Zhang is highly rated in 14 conditions, according to our data. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Nephrectomy, and Tissue Biopsy.

Her clinical research consists of co-authoring 139 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
2201 Inwood Rd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Device
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Apalutamide, Androgen deprivation, Docetaxel
Study Phase: Phase 2
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer
TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer
Enrollment Status: Withdrawn
Publish Date: July 07, 2020
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

5 Total Publications

A Green Synthesis Route to Derive Carbon Quantum Dots for Bioimaging Cancer Cells.
A Green Synthesis Route to Derive Carbon Quantum Dots for Bioimaging Cancer Cells.
Journal: Nanomaterials (Basel, Switzerland)
Published: May 24, 2023
Similar Doctors
Expertise in
16
conditions
Dr. David E. Gerber
Oncology | Hematology
Expertise in
16
conditions
Dr. David E. Gerber
Oncology | Hematology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, Dermatology, 
Dallas, TX 
 (0.4 miles away)
214-645-2400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Gerber is an Oncologist and a Hematologist in Dallas, Texas. Dr. Gerber is highly rated in 16 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Endoscopy.

Joyce A. O'shaughnessy
Expertise in
12
conditions
Dr. Joyce A. O'shaughnessy
Oncology | Internal Medicine
Expertise in
12
conditions
Dr. Joyce A. O'shaughnessy
Oncology | Internal Medicine

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (4.3 miles away)
972-449-0540
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joyce O'shaughnessy is an Oncologist and an Internal Medicine provider in Dallas, Texas. Dr. O'shaughnessy has been practicing medicine for over 43 years is highly rated in 12 conditions, according to our data. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, HER2 Negative Breast Cancer, and Tissue Biopsy.

Expertise in
10
conditions
Dr. Hans J. Hammers
Oncology
Expertise in
10
conditions
Dr. Hans J. Hammers
Oncology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (0.4 miles away)
214-645-8300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans Hammers is an Oncologist in Dallas, Texas. Dr. Hammers is highly rated in 10 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Wilms Tumor, Nephrectomy, and Thrombectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhang's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile